Monashee Investment Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Monashee Investment Management’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$3.23M	–	131
2021 Q3	$3.23M	Buy	10,000 +7,547	+308%	+$2.2M	0.6%	36
2021 Q2	$637K	Sell	2,453 -2,547	-51%	-$776K	0.08%	226
2021 Q1	$1.93M	Sell	5,000 -5,000	-50%	-$2.02M	0.3%	111
2020 Q4	$4.18M	Buy	+10,000	New	+$3.15M	0.55%	40
2020 Q3	–	Sell	-10,000	Closed	-$1.99M	–	271
2020 Q2	$1.99M	Buy	+10,000	New	+$1.98M	0.3%	100

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Monashee Investment Management's VINC Position: Q4 2021 in Review

Monashee Investment Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2021, closing a stake of 10,000 shares — an estimated $3.23M sold.

Monashee Investment Management first reported a position in VINC in Q2 2020 and held it in 5 quarters. The position peaked at $4.18M in Q4 2020. 55 funds tracked by Wall St. Rank hold VINC as of Q4 2021.

Monashee Investment Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Monashee Investment Management sold 10,000 Vincerx Pharma, Inc. Common Stock shares in Q4 2021, an estimated $3.23M.
Monashee Investment Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Monashee Investment Management's Vincerx Pharma, Inc. Common Stock position peaked at $4.18M in Q4 2020.
55 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2021.

Based on Monashee Investment Management's 13F filing for Q4 2021, filed 7 Feb 2022.